Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Condition:   Major Depressive Disorder With Suicidal Ideation With Intent Interventions:   Drug: MIJ821 Intravenous Injection;   Drug: Placebo Intravenous Injection Sponsor:   Novartis Pharmaceuticals Not yet recruiting

Source: ClinicalTrials.gov - January 25, 2021 Category: Research Source Type: clinical trials